DEPARTMENT OF HEALTH AND HUMAN SERVICES

Determination Concerning a Petition To Add a Class of Employees to the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HHS gives notice of a determination concerning a petition to add a class of employees from the Carborundum Company, in Niagara Falls, New York, to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA).

FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 1–877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV.

SUPPLEMENTARY INFORMATION: Authority: 42 U.S.C. 7384q.

On November 16, 2017, the Acting Secretary of HHS determined that the following class of employees does not meet the statutory criteria for addition to the SEC as authorized under EEOICPA:

All employees who worked in any area of the Carborundum Company facility on Buffalo Avenue, Niagara Falls, New York, from January 1, 1943, through December 31, 1976.

John Howard, Director, National Institute for Occupational Safety and Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made on the part of Matthew Endo, former graduate student, Department of Chemistry, University of Illinois at Urbana-Champaign. The questioned research was supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM080436. The administrative actions, including three (3) years of supervision, which are implemented beginning on November 16, 2017, are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Matthew Endo, University of Illinois at Urbana-Champaign: Based on the Respondent’s admission, an assessment conducted by University of Illinois at Urbana-Champaign (UIUC), and analysis conducted by ORI in its oversight review, ORI found that Mr. Matthew Endo, a former graduate student, Department of Chemistry, UIUC, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM080436.

ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly causing false data to be recorded, falsifying and/or fabricating data and related images by alteration and/or reuse and/or relabeling of experimental data, and reporting falsified and/or fabricated data in one manuscript subsequently submitted for publication:

• “Amphotericin primarily kills human cells by binding and extracting cholesterol.” Submitted for publication to the Proceedings of the National Academy of Sciences [withdrawn prior to peer review] (hereafter referred to as “Manuscript 1”)

Specifically, ORI found that:

• In Manuscript 1, Respondent caused falsified and/or fabricated results to be recorded by knowingly requesting biological testing of a mixture of compounds that he falsely claimed to be a single compound

• In Manuscript 1, Respondent falsified and/or fabricated the results on page S26 of the Supporting Information by modifying the HPLC trace through peak erasure to make the preparation of C35deoOAmB appear more pure than in the actual results of experimentation

• In Manuscript 1, Respondent falsified and/or fabricated the results of Surface Plasmon Resonance data on page S7 of the Supporting Information to make the error bars smaller than the actual results of experimentation

• In Manuscript 1, Respondent falsified and/or fabricated the results of a WST08 Cell Proliferation Assay on page S32 of the Supporting Information by falsely claiming to run the reaction in triplicate when it was only performed in duplicate

• In correspondence with his advisor, Respondent falsified and/or fabricated the results of the preparation of putative C2deoAmB where Respondent modified and relabeled a HPLC trace and relabeled an NMR spectrum to falsely claim characterization, purity, and identification of sample that was sent for biological assay

Mr. Endo entered into a Voluntary Settlement Agreement and voluntarily agreed for a period of three (3) years, beginning on November 16, 2017:

(1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for PHS support for a research project on which Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of Respondent’s duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that he will not participate in any PHS-supported research until a plan for supervision is submitted and approved by ORI;

(2) that any institution employing him must submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are
accurately reported in the application, report, manuscript, or abstract;

(3) if no supervisory plan is provided to ORI, to provide certification to ORI on annual basis that he has not engaged in, applied for, or had his name included on any application, proposal, or other request for PHS funds without prior notification to ORI; and

(4) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

Kathryn M. Partin,
Director, Office of Research Integrity.

[FR Doc. 2017–29691 Filed 12–14–17; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

ACTION: Notice.


FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 1–877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV.

SUPPLEMENTARY INFORMATION:
Authority: [42 U.S.C. 7384q].

On November 16, 2017, the Acting Secretary of HHS determined that the following class of employees does not meet the statutory criteria for addition to the SEC as authorized under EEOICPA:

All employees of the Department of Energy, its predecessor agencies, and their contractors and subcontractors who worked in any area of the Rocky Flats Plant in Golden, Colorado, from January 1, 1984, through December 31, 2005.

John Howard,
Director, National Institute for Occupational Safety and Health.

[FR Doc. 2017–27040 Filed 12–14–17; 8:45 am]
BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Pre and Postnatal Neurologic Disorders.

Date: December 19, 2017.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).

Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, 301–435–1259, nadi@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.


Dated: December 12, 2017.

Sylvia L. Neal.
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–27108 Filed 12–14–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the meeting of the Council of Councils.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov).

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Council of Councils.
Open: January 26, 2018.
Time: 8:15 a.m. to 11:30 a.m.
Agenda: Call to Order and Introductions; Announcements and Updates; Common Fund 4D Nucleome Presentation; NIH Update; Common Fund Concepts.
Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Closed: January 26, 2018.
Time: 12:15 p.m. to 1:30 p.m.
Agenda: Review of Grant Applications.
Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Open: January 26, 2018.
Time: 1:30 p.m. to 4:00 p.m.
Agenda: Tribal Health Research Office Update and Input; Introduction of New Working Group to Council of Councils; Update & Input—Office of Research on Women’s Health Strategic Plan; The ECHO Program at Year One; Closing Remarks.
Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Contact Person: Franziska Grieder, D.V.M., Ph.D., Executive Secretary, Director, Office of Research Infrastructure Programs, Division of